Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to
evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation
after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured
by PET/CT.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Cape Town
Collaborators:
University of Bern University of Namibia University of Stellenbosch University of Zurich